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ABSTRACT
Objectives: This article explores the application of cost-
effectiveness analysis in a comparison of eletriptan and
sumatriptan in the acute treatment of migraine.
Methods: The study employs data from a randomized,
double-blind, placebo-controlled clinical trial comparison
of oral eletriptan (40 and 80 mg) and oral sumatriptan
(50 and 100 mg). Analyses were undertaken using two
composite measures of treatment outcome constructed to
reﬂect the requirements of patients more comprehensively
than the conventional efﬁcacy indicator of headache
response at 2 hours. On the cost side of the equation,
reﬂecting the health-care system perspective of the analy-
sis, drug costs for initial dosing, second dosing for non-
response, and recurrence and rescue medication were
taken into account.
Results: The analysis found that eletriptan treatment
resulted in lower costs per successfully treated attack than
those of sumatriptan under both outcome criteria.
Conclusion: Further reﬁnement of outcomes measure-
ment in migraine would be valuable and eletriptan has a
potentially important role to play in the cost-effective
management of the disorder.
Keywords: cost-effectiveness, economic evaluation, elet-
riptan, migraine, sumatriptan.
Introduction
The arrival during the 1990s of a new, speciﬁc class
of medicines for treating acute migraine attacks (the
serotonin 5-HT1B/1D receptor agonists) has given rise
to considerable interest in the economics of
migraine and its management. Early pharmacoeco-
nomic research in this area concentrated on the cost
of the illness [1–4]. These studies revealed a general
pattern of relatively low direct care costs but sub-
stantial indirect costs attributable to absence from,
or reduced effectiveness at, work during migraine
attacks [5,6]. This information has played an
important role in raising professional and public
awareness of the disorder, identifying the signiﬁcant
drivers of cost and in enabling comparisons to be
made with the burdens of other diseases. However,
cost-of-illness data are of little help in guiding efﬁ-
cient health-care resource allocation [7,8]. These
data only establish current levels of resource con-
sumption without demonstrating whether they are
appropriate or if further resources should be
directed to the management of the disorder in ques-
tion. Decision making in this regard should be
informed by the cost-effectiveness of available treat-
ment options, not by the cost of the disease [9].
The shifting balance now emerging in the litera-
ture away from cost of migraine studies toward
treatment-speciﬁc economic evaluations is conse-
quently a positive development. It is also timely
given the increasing emphasis health authorities are
placing on maximizing the return, or health gain,
from available health-care resources. However, the
evaluations currently being reported frequently pur-
sue different objectives in a variety of care settings
while employing differing methodologies and end
points [10–18]. Clinicians and other decision mak-
ers are therefore able to draw on a growing volume
of information about the value of speciﬁc treatment
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options but often ﬁnd it difﬁcult to compare the
results generated by the different studies. Against
this background and given the increasing number of
antimigraine treatments becoming available for pre-
scription use, a more consistent approach to evalu-
ation would be helpful.
Cost-effectiveness analysis is a technique of
economic evaluation that facilitates comparisons of
the costs and outcomes of health-care interventions.
It could therefore provide a useful framework for
examining the value-for-money characteristics of
competing antimigraine therapies [19]. This article
explores the application of this methodological
approach in a comparison of the cost-effectiveness
of oral sumatriptan, the ﬁrst-launched and currently
most widely prescribed serotonin 5-HTIB/ID agonist
for treating migraine attacks, with eletriptan, a
more recent innovation in this class of agents.
Methods
The cost-effectiveness analysis was based on data
gathered in a randomized, double-blind, double-
dummy, placebo-controlled Phase III clinical trial
comparing two doses of oral eletriptan (40 and
80 mg) and two doses of oral sumatriptan (50 and
100 mg) in the treatment of migraine [20].
Although not designed primarily for economic eval-
uation, the study had collected sufﬁcient data to
form the basis of a cost-effectiveness analysis. An
analytical framework was therefore established a
priori and subsequently applied to the clinical trial
data set.
The clinical trial extended over three attacks (or
for a maximum of 12 weeks) but only the ﬁrst of
these was employed for the cost-effectiveness anal-
ysis. This approach not only simpliﬁed the analysis,
it also maximized the number of patients available
for inclusion in the economic evaluation. By focus-
ing on the initial attack only, any problems poten-
tially linked to some patients subsequently deciding
not to continue to participate in the clinical trial
were avoided. In addition, conﬁning attention to the
ﬁrst attack meant that treatment responses would
not be inﬂuenced by prior exposure to the two med-
icines. The exclusion criteria for the clinical trial
required that patients should not previously have
used either eletriptan or sumatriptan. Finally, reas-
surance that the ﬁrst attack is representative can be
drawn from evidence about consistency of response.
The conventional 2-hour headache response rates in
the ﬁrst attack were within 2.5% of the average for
all three attacks for eletriptan 40 mg and both dos-
age strengths of sumatriptan. For eletriptan 80 mg,
the corresponding response rate was 3.2% less than
the three-attack average.
During the attack, patients were randomized to
one of the seven treatment sequences shown in
Table 1. A treatment sequence consisted of an initial
dose to be taken following the onset of migraine
with headache of severe or moderate intensity. The
second treatment in the sequence could be taken if
there was a lack of response 2 hours after the initial
dosing, that is, if headache had failed to ameliorate
to mild or resolve completely to pain-free from the
baseline status of either severe or moderate. Rescue
medication was allowed from 2 hours after this sec-
ond dose if required. A second dose of the study
drugs was also permissible if the headache, having
initially responded positively by 2 hours, recurred
with moderate or severe intensity within a period of
24 hours from the ﬁrst treatment.
For the purpose of this cost-effectiveness study,
only those eletriptan treatment sequences in which
active drug was available throughout the attack
were compared with the sumatriptan arms of the
trial. Patients who were randomized to treat the
attack with eletriptan 40 mg or eletriptan 80 mg as
a ﬁrst dose and who would then have received, if
required, placebo as a second dose for either non-
response or headache recurrence have therefore
been excluded. Patients randomized to these active
drug/placebo sequences have been excluded from
the analysis even if they only required the ﬁrst dose
to manage the migraine attack. Such sequences,
although relevant to a Phase III trial assessing the
efﬁcacy and safety of a second dose, would not be
employed in the management of migraine in clinical
practice. In the sumatriptan 50 and 100 mg groups,
all patients received, if required, sumatriptan 50 or
100 mg as the second dose, respectively.
In the following sections, the notation E40/E40
refers to patients who were randomized to the treat-
ment sequence in which eletriptan 40 mg was used
as the ﬁrst dose and was also available, if needed, as
the second dose for treating either nonresponse or
recurrence. The notation E80/E80 applies in a cor-
Table 1 Treatment sequences for the ﬁrst attack
Treatment
sequence First dose Second dose
1 Eletriptan 40 mg Eletriptan 40 mg
2 Eletriptan 40 mg Placebo
3 Eletriptan 80 mg Eletriptan 80 mg
4 Eletriptan 80 mg Placebo
5 Sumatriptan 50 mg Sumatriptan 50 mg
6 Sumatriptan 100 mg Sumatriptan 100 mg
7 Placebo Placebo
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responding way to eletriptan 80 mg. Finally, S50/
S50 and S100/S100 refer to the sumatriptan 50 and
100 mg treatment sequences, respectively.
Outcomes
In cost-effectiveness analysis, it is important that the
outcome chosen (that is, the measure of treatment
success) is of relevance to the patient. Clinical stud-
ies of migraine therapies have almost universally
employed headache response at 2 hours after initial
dosing as the primary indicator of treatment efﬁ-
cacy [21]. Speciﬁcally, assessment has centered on
the percentage of patients improving from severe or
moderate headache at baseline to mild headache or
no pain at 2 hours. By itself, however, this measure
has limited clinical meaning and only partially
reﬂects what may be important to migrainers. It
fails to differentiate, for example, between treat-
ments generating a substantial improvement in
migraine headache from severe at the start of treat-
ment to pain-free 2 hours later and those only amel-
iorating the pain from moderate to mild over the
same time period. In addition, effective treatment
will embrace, from the patient’s perspective, char-
acteristics other than just headache response at 2
hours—such as the speed with which pain relief is
obtained and normal functioning can be resumed as
well as the likelihood of headache recurrence. A
quicker and sustained response also has economic
implications: for example, an individual suffering a
migraine attack may be less likely to cease work if
she or he begins to feel better after a short period of
time.
The primary clinical trial efﬁcacy end point—
headache response at 2 hours—may therefore be
argued to be too narrow a deﬁnition of treatment
success for incorporation into a cost-effectiveness
analysis. The present study consequently proposes
and utilizes two alternative and more comprehen-
sive measures of outcome. Both are composite in
nature and are feasible because patients recorded
their headache status at multiple time points during
the clinical trial—immediately prior to ﬁrst dosing
and then at 0.5, 1, 2, 4, and 24 hours after treat-
ment—as well as information about recurrence and
the use of rescue medication.
The ﬁrst of these measures identiﬁes successful
treatment as the achievement of pain-free headache
status at 2 hours, no recurrence within 24 hours of
the ﬁrst dosing, and no requirement for rescue med-
ication (pathways 1, 3, 14, 16, 27, and 29 in Fig. 1).
This deﬁnition of successful treatment has the same
construction as “sustained pain-free” [22]—which
is attracting increasing interest among those inves-
tigating migraine treatments—but will be referred
to as success measure 1 (SM1) in the present anal-
ysis. The second and more demanding outcome
measure constructed for the cost-effectiveness anal-
ysis, hereafter designated SM2, deﬁnes successful
treatment as a positive headache response at 1 hour,
that is, an improvement from severe or moderate at
baseline to mild or better, followed by the achieve-
ment of pain-free status by 2 hours, which is sus-
tained at 4 hours and the absence of headache
Figure 1 A framework for assessing the outcomes of treating a
migraine attack. PF, pain-free; R, response; NR, nonresponse; Rec,
recurrence; N, no; Y, yes.
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recurrence within 24 hours of the ﬁrst dose (path-
ways 1 and 14 in Fig. 1).
With each of the deﬁnitions of successful treat-
ment, attacks were classiﬁed into one of three cat-
egories. An attack was deﬁned as successfully
treated if all of the relevant assessments at the time
points speciﬁed above were available and if the out-
comes satisﬁed the deﬁnitions for success at each of
these time points. An attack was classiﬁed as not
successfully treated if any one of the assessments
required for an outcome was negative, that is, did
not meet the criteria for successful treatment. It
should be noted that classiﬁcation into this category
does not require the availability of all time point
assessments. Focusing on SM2, for example, a
patient whose 1 hour assessment was missing but
who was otherwise a pain-free responder at 2 and
4 hours until experiencing a recurrence within
24 hours of ﬁrst dose would have had her/his attack
classiﬁed as not successfully treated because the
recurrence would have been sufﬁcient to result in
classiﬁcation in this way.
An attack was classiﬁed as not evaluable if any of
the assessments required to determine treatment
outcome was missing, all other available assess-
ments each individually satisfying the deﬁnition of
successful treatment. For example, under SM2, a
patient with a missing assessment at 1 hours, who
was pain-free at 2 and 4 hours, with no headache
recurrence within 24 hours of ﬁrst dose would have
had the attack classiﬁed as not evaluable. Attacks
were also classed as not evaluable if baseline head-
ache severity was not rated as either moderate or
severe.
Costs
Reﬂecting the health-care system perspective of the
analysis, the cost side of the cost-effectiveness equa-
tion comprises the costs of all headache medications
used by patients up to 24 hours after ﬁrst dose
for those who did not experience headache recur-
rence and up to 24 hours after treatment for recur-
rence for those patients who did recur. It includes
both study drugs and rescue medication. For
sumatriptan, the cost for each dose was calculated
as a simple mean of the prices of individual tablets
in the 6 and 12 tablet packs for the 50 mg dose and
in the 6 and 12 tablet packs for the 100-mg dose.
These data were taken from the March 2002 edition
of the British National Formulary [23] and reﬂect
net prices to the UK National Health Service.
Following this approach, the prices employed in
the study were £4.83 for the 50-mg tablet of
sumatriptan and £8 for the 100-mg dose. For elet-
riptan, the price to the UK NHS is £3.75 for the 40-
mg tablet, implying a cost of £7.50 for an 80-mg
dose.
The costs of rescue medication used by patients
in the study are difﬁcult to estimate with accuracy.
The case report forms used in the clinical trial only
recorded the name of medication employed for res-
cue and did not provide any information about dos-
age. In addition, rescue medications, both single
and combination compounds, were often recorded
generically and precision in costing is not possible
because the identity of the medicine supplier is
unknown. These difﬁculties are further exacerbated
by the fact that the study was conducted in 15 coun-
tries. Against this background, it was decided that
an average cost per rescue medication usage would
be derived rather than attempt to cost each individ-
ual drug employed for this purpose.
From the rescue medications listing, attention
was focused on those medicines employed on ﬁve or
more occasions. For each of these, the average dose
recommended in the British National Formulary
[23] and its net price to the UK NHS was obtained.
This information was combined with the frequency
with which each of these particular medicines was
used, as recorded in the rescue medications listing,
and the products summed to yield a weighted aver-
age cost per unit of rescue medication. This meth-
odology resulted in an average cost of just £0.07 per
usage of rescue medication, indicating that the
choice of approach to estimating this cost compo-
nent will have little impact on the study results.
The costs of other elements of health-care
resource utilization associated with the manage-
ment of migraine were not gathered in the clinical
trial and have not been included in the cost-
effectiveness analysis. However, the exclusion of
these other expenditures does not devalue the cost-
effectiveness analysis reported here because medi-
cines are a signiﬁcant component of migraine
management costs and an increasing number of
agents has become available in recent years. A study
for the Ofﬁce of Health Economics in the early
1990s found that prescription pharmaceuticals
accounted for 68% of total NHS costs for migraine
[24]. A corresponding proportion of 41% was
reported for the Netherlands [25].
Finally, the cost per successfully treated attack
(CPSTA) for each of the four active medication dos-
ages (eletriptan 40 and 80 mg, sumatriptan 50 and
100 mg) was derived by dividing the total cost of
treating all evaluable attacks by the number of those
successfully treated as deﬁned by the two composite
outcome measures described earlier. To test the
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robustness of the results, sensitivity analysis was
applied to the values for both outcomes and costs.
Statistical Methods
The numbers of successfully treated attacks in the
four treatment sequence groups were calculated and
compared using logistic regression. This method
was adopted because it is an efﬁcient means of ana-
lyzing data presented as proportions and easily han-
dles the case where four treatment groups need to
be compared simultaneously. The logit of the pro-
portion of successfully treated attacks was the
response measure, with the treatment group ﬁtted
as a single categorical explanatory variable. The
treatment groups’ comparisons were E40/E40 ver-
sus S50/S50, E40/E40 versus S100/S100, E80/E80
versus S50/S50, and E80/E80 versus S100/S100.
Adjustments for multiple comparisons were not
made since the above were only performed to show
that the beneﬁt of eletriptan over sumatriptan with
respect to the number of successfully treated attacks
was consistent with the beneﬁt already seen in the 2-
hour headache response rate reported in the clinical
trial.
The CPSTA was calculated for each of the four
treatment sequence groups, for each success crite-
rion, as previously deﬁned. Ninety-ﬁve percent con-
ﬁdence intervals for the CPSTA for each treatment
sequence group and treatment group comparisons
were obtained using bootstrap techniques [26]. All
four treatment comparisons were of interest; thus,
no formal adjustment for multiple comparisons was
performed since precise P values have been quoted
to demonstrate the extent of statistical signiﬁcance.
However, for completeness, an adjustment for mul-
tiple comparisons using the Bonferroni method as a
sensitivity analysis was undertaken. All statistical
analyses were performed using SAS 6.12 statistical
software.
Results
The numbers of attacks classed as evaluable for
each treatment sequence group under each success
criterion are presented in Table 2: 97% and 96% of
treated attacks were classed as evaluable for the
analyses using success criteria SM1 and SM2,
respectively. The number of attacks evaluable for
the analysis using success criterion SM1 was slightly
larger than the number evaluable using success cri-
terion SM2. This is because the SM1 criterion used
only the 2-hour assessment, while the SM2 criterion
required assessments at 1, 2, and 4 hours, and
therefore some attacks with missing 1- or 4-hour
assessments that were classed as not evaluable
under SM2 were classed as successfully treated
under SM1.
Only a small number of attacks were classed as
nonevaluable because of missing assessments: 11
(2%) of 524 for SM1 and 16 (3%) of 524 for SM2.
These proportions were consistent in each of the
four treatment groups. Nonevaluable attacks have
been omitted from the analysis because of the sim-
ilar, relatively small numbers involved and because
it is reasonable to assume that the reasons for the
missing assessments were consistent across the four
treatment groups and not due to any differences
in treatment effects. Finally, an additional three
attacks were classed as nonevaluable because base-
line headache severity was not rated as moderate or
severe.
Table 2 also shows that the number of attacks in
each of the two treatment sequences involving elet-
riptan was about half that in the groups employing
sumatriptan. This reﬂects the design of the clinical
study whereby the comparison of treatment efﬁcacy
using the 2-hour headache response rate was to be
based, for eletriptan, on the combined data from the
two sequences where the same dose of the drug was
given ﬁrst (i.e., E40/E40 plus E40/placebo and E80/
E80 plus E80/placebo). Summing in this way would
yield similar numbers of attacks in each of the elet-
riptan-combined groups to those in the individual
sumatriptan groups.
Table 3 presents the demographic distribution of
the patients whose attacks were evaluable under
each success criterion: in both instances, the four
treatment sequence groups were fairly well matched
with regard to gender and age.
For both success criteria, a greater proportion
of successfully treated attacks occurred in the
two eletriptan treatment groups than in the
sumatriptan arms (Table 4). Using success criterion
SM1, the E40/E40 and E80/E80 groups had 30 and
Table 2 Number of evaluable attacks under the two suc-
cessful treatment criteria
Treatment
group
Total numbers of
attacks treated
Evaluable for
SM1*
Evaluable for
SM2†
E40/E40 93 91 91
E80/E80 83 80 79
S50/S50 181 177 176
S100/S100 170 165 162
Total (%) 527 (100) 513 (97) 508 (96)
*Attacks successfully treated if pain-free at 2 hours with no subsequent recur-
rence and no use of rescue medication.
†Attacks successfully treated if respond at 1 hour and pain-free at 2 and 4 hours
with no subsequent recurrence.
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33% of attacks successfully treated, respectively,
compared with 12 and 15% of attacks in the S50/
S50 and S100/S100 groups. All four comparisons
between E40/E40 and S50/S50, E40/E40 and S100/
S100, E80/E80 and S50/S50, and E80/E80 and
S100/S100 were statistically signiﬁcant (P < .01 for
all comparisons).
With success criterion SM2, 18 and 22% of
attacks managed with E40/E40 and E80/E80,
respectively, were successfully treated, compared to
8 and 10% of those treated with S50/S50 and S100/
S100. The differences between E40/E40 and S50/
S50, between E80/E80 and S50/S50, and between
E80/E80 and S100/S100 were all statistically signif-
icant (P = .021, P = .003, and P = .016, respec-
tively). The difference between E40/E40 and S100/
S100 was close to reaching statistical signiﬁcance
(P = .082).
When costs are taken into account, Table 5
shows that the two eletriptan treatment groups had
a lower CPSTA than the two sumatriptan treatment
groups under both success criteria. For SM1, the
costs in the eletriptan 40- and 80-mg groups were
£17.55 and £31.76, compared with estimates for
sumatriptan 50 and 100 mg of £63.98 and £80.50,
respectively (P < .024 for all comparisons). For
SM2, the estimated CPSTA in the eletriptan 40 and
80 mg groups was £29.61 and £48.13 compared to
corresponding costs in the sumatriptan 50 and
100 mg groups of £95.63 and £124.28, respectively
(E40/E40 vs. S50/S50, P = .013; E40/E40 vs. S100/
S100, P = .009; E80/E80 vs. S50/S50, P = .067;
E80/E80 vs. S100/S100, P = .035).
If an adjustment for multiple treatment compar-
isons is made using the Bonferroni method, three
of four comparisons for SM1 remain statistically
signiﬁcant at the 0.05 level. For SM2, the compar-
ison of E40/E40 versus S100/S100 stays statisti-
cally signiﬁcant at the .05 level, the comparison of
E40/E40 versus S50/S50 approaches statistical sig-
niﬁcance (adjusted P = .052) but the comparisons
of E80/E80 against the two sumatriptan sequences
Table 3 Distribution (%) of patients by gender and age group for each success criterion
Treatment
group:
Criterion SM1* (N = 513) Criterion SM2† (N = 508)
E40/E40
(n = 91)
E80/E80
(n = 80)
S50/S50
(n = 177)
S100/S100
(n = 165)
E40/E40
(n = 91)
E80/E80
(n = 79)
S50/S50
(n = 176)
S100/S100
(n = 162)
Gender
Male 14 10 10 12 14 10 10 12
Female 86 90 90 88 86 90 90 88
Age group (years)
<18 0 0 1 0 0 0 1 0
18–29 17 28 25 22 17 27 25 23
30–45 57 48 53 52 58 48 53 52
>45 26 25 22 26 25 25 21 25
*Attacks successfully treated if pain-free at 2 hours with no subsequent recurrence and no use of rescue medication.
†Attacks successfully treated if respond at 1 hour and pain-free at 2 and 4 hours with no subsequent recurrence.
Table 4 Numbers of successfully treated attacks
Success
criterion
Treatment
group
2-hour headache
response
rates (%)*
Number of
evaluable attacks
Number of  
successfully treated 
attacks† (%)
Treatment  
comparison P value‡
SM1§ E40/E40 64 91 27 (30)
E80/E80 67 80 26 (33) E40/E40 vs. S50/S50 <0.001
E40/E40 vs. S100/S100 0.007
E80/E80 vs. S50/S50 <0.001
S50/S50 50 177 21 (12) E80/E80 vs. S100/S100 0.002
S100/S100 53 165 25 (15)
SM2|| E40/E40 64 91 16 (18)
E80/E80 67 79 17 (22) E40/E40 vs. S50/S50 0.021
E40/E40 vs. S100/S100 0.082
E80/E80 vs. S50/S50 0.003
S50/S50 50 176 14 (8) E80/E80 vs. S100/S100 0.016
S100/S100 53 162 16 (10)
*Percentage of attacks improving from severe or moderate at baseline to mild or pain-free at 2 hours.
†Attacks successfully treated according to the relevant criteria SM1 or SM2.
‡Based on logistic regression model with treatment as the single explanatory variable.
§Attacks successfully treated if pain-free at 2 hours with no subsequent recurrence and no use of rescue medication.
||Attacks successfully treated if respond at 1 hour and pain-free at 2 and 4 hours with no subsequent recurrence.
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S50/S50 and S100/S100 become nonsigniﬁcant
(adjusted P = .266 and .140, respectively).
Discussion
The average cost-effectiveness ratios shown in
Table 5 reveal an economic advantage for eletriptan
over sumatriptan. Indeed, in most of the compari-
sons eletriptan is the dominant option since it is
both more effective and less expensive than
sumatriptan. In spite of the fact that this study was
not powered to detect changes in these outcomes,
only in the comparison of eletriptan 80 mg and
sumatriptan 50 mg using the more demanding SM2
outcome measure is a statistically signiﬁcant differ-
ence not quite achieved. Application of the Bonfer-
roni adjustment results in a loss of statistical
signiﬁcance for E80/E80 versus S50/S50 under SM1
and for E80/E80 versus S50/S50 and S100/S100
using the SM2 criterion. The method is, however,
conservative in that it errs on the side of nonsignif-
icance [27]. Other less conservative methods for
adjusting for multiple comparisons are available
and would give different P values. The strength of
the evidence and the conclusions regarding the
relative beneﬁt of eletriptan over sumatriptan are
therefore best assessed using the mean CPSTA
and the 95% conﬁdence intervals that remain
unchanged, regardless of the method used for
adjusting for multiple comparisons.
The magnitude of this advantage is compelling
but it remains important to ascertain the robustness
of the results and this requires two key issues to be
addressed. First, are the clinical trial ﬁndings uti-
lized here sufﬁciently representative to provide the
foundation for the cost-effectiveness analysis? Sec-
ond, two alternative outcome measures were
employed for the economic evaluation. It is clear,
however, that many potential options exist and it is
therefore important to establish that the SM1 and
SM2 constructs are relevant and accord with cur-
rent thinking in this area.
Representativeness of the Clinical Trial
The conventional 2-hour headache response rates
found in the clinical trial for eletriptan 40 and
80 mg and for sumatriptan 50 and 100 mg were 64,
67, 50, and 53%, respectively [20]. Broadening the
perspective, a meta-analysis of the seven eletriptan
phase II/III clinical studies conducted mainly in
Europe and the United States found equivalent
response rates of 60 and 66% for the 40- and 80 mg
Table 5 Cost per successfully treated attack (CPSTA)
Success 
criterion
Treatment
group
Total number
of doses of
study medication
used by evaluable
subjects
Total number
of rescue
medications
used by
evaluable subjects
Number of
successfully
treated
attacks* (%)
Total
cost of
treatment
(£)
CPSTA (£)
(95% CI)
Treatment 
comparison P value
Adjusted
P value†
SM1‡ E40/40 126 18 27 (30%) 473.76 17.55 
(13.32–24.85)
E80/E80 110 11 26 (33%) 825.77 31.76
(24.11–45.43)
E40/E40 vs.
S50/S50
<0.001 0.002
E40/E40 vs.
S100/S100
<0.001 0.002
E80/E80 vs.
S50/S50
0.024 0.096
S50/S50 277 82 21 (12%) 1343.65 63.98
(46.27–97.31)
E80/E80 vs.
S100/S100
<0.005 0.020
S100/S100 251 64 25 (15%) 2012.48 80.50 
(60.52–119.84)
SM2§ E40/40 126 18 16 (18%) 473.76 29.61 
(21.27–45.83)
E80/E80 109 11 17 (22%) 818.27 48.13
(33.16–73.69)
E40/E40 vs.
S50/S50
0.013 0.052
E40/E40 vs.
S100/S100
0.009 0.034
E80/E80 vs.
S50/S50
0.067 0.266
S50/S50 276 82 14 (8%) 1338.82 95.63
(66.25–167.91)
E80/E80 vs.
S100/S100
0.035 0.140
S100/S100 248 63 16 (10%) 1988.41 124.28 
(87.89–205.30)
*Attacks successfully treated according to the relevant criteria SM1 or SM2.
†P value adjusted for multiple comparisons using Bonferroni method.
‡Attacks successfully treated if pain-free at 2 hours with no subsequent recurrence and no use of rescue medication.
§Attacks successfully treated if respond at 1 hour and pain-free at 2 and 4 hours with no subsequent recurrence.
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doses, respectively (Pﬁzer, data on ﬁle). Focusing
only on the three clinical studies in which
sumatriptan was an active comparator, the corre-
sponding eletriptan efﬁcacy rates were 64 and 71%,
respectively, while those for sumatriptan reached
53% for the 50-mg dose and 54% for the 100-mg
dose [28].
Other clinical studies of sumatriptan—that is,
investigations undertaken outside the eletriptan
trial program—have reported a range of efﬁcacy
ﬁndings. A review by Tfelt-Hansen [29] of 12 pla-
cebo-controlled double-blind randomized clinical
trials of sumatriptan 100 mg found a 2-hour head-
ache response rate ranging from 46% to 67%.
Combining the results of these published studies
yielded an overall response rate of 58%. A more
recently published review by the same author and
colleagues [30] extended the coverage to 20 clinical
investigations involving 3090 patients treated with
sumatriptan 100 mg and calculated an almost iden-
tical combined 2-hour headache response rate of
59%.
The 50-mg dose of oral sumatriptan has been
investigated to a lesser extent than its 100-mg coun-
terpart. In their review published in 2000, Tfelt-
Hansen and colleagues [30] identiﬁed seven relevant
clinical trials. Based on a total of 1599 patients
treated with the drug, the meta-analysis found a 2-
hour headache response rate of 59%.
Assessing the representativeness of a single clin-
ical study is not straightforward. Many variables
might be compared. As well as the 2-hour headache
response rate discussed above, attention might also
be given to pain-free rates at 2 hours or other time
points, therapeutic gain rates (calculated as the efﬁ-
cacy rate of the active agent minus that observed for
placebo), and the incidence of recurrence. In addi-
tion, the number of attacks over which these varia-
bles might be studied and the differing ways in
which the data might be analyzed give rise to fur-
ther potential complexity. Nevertheless, the 2-hour
headache response rate is the most widely used pri-
mary end point, and assuming there is consistency
between it and the composite outcome measures
underpinning the economic analyses reported in this
article, the evidence suggests that the clinical trial
supplying the data for the cost-effectiveness analysis
can be considered to be broadly representative.
Furthermore, even if the composite treatment
success rates employed in the cost-effectiveness
analysis for eletriptan (Table 4) are reduced by an
amount to reﬂect the slightly lower primary efﬁcacy
rates reported from the eletriptan trial program as a
whole and, likewise, the sumatriptan success rates
are increased to mirror the efﬁcacy levels found by
meta-analyses performed by Tfelt-Hansen et al.
[30], the advantage of eletriptan over sumatriptan
remains (Table 6). Employing the SM1 measure of
outcome, the CPSTA for eletriptan is still less than
50% of that for sumatriptan (34% for eletriptan
40 mg and 45% for eletriptan 80 mg). Finally, tak-
ing costs into account, sensitivity analysis indicates
that even with these revisions to treatment success
rates, the prices for eletriptan—£3.75 for 40 mg
and £7.50 for 80 mg—would have to rise substan-
tially to generate the same CPSTA as sumatriptan.
Thus, under SM1, the cost of eletriptan 40 mg
would need to reach £10.95 per dose to achieve par-
ity of CPSTA with sumatriptan 50 mg and that of
eletriptan 80 mg would need to be £16.70 to result
in the same CPSTA as sumatriptan 100 mg.
Deﬁnition of  Treatment Success
In recent years, there has been growing interest in
measures of treatment outcome that are more com-
prehensive and meaningful to patients than the con-
ventional efﬁcacy end point of headache response at
2 hours [31]. In particular, considerable attention
has been given to the concept of “sustained pain-
free” which is deﬁned as pain-free by 2 hours after
dosing with no recurrence and no use of rescue
medication 2 to 24 hours postdose [22]. This meas-
ure is increasingly being advocated by a number of
opinion leaders and has recently been employed in a
Table 6 Sensitivity analysis for SM1 treatment outcome results
Treatment
Conventional 2-hour headache response rate (%) SM1 success rates (%)
(a) This study
(b) Seven eletriptan studies
(Pﬁzer, data on ﬁle)/Tfelt-Hansen [30]
% Difference between
 (a) and (b) This study Adjusted
E40 64 60 -6.25 30 28
E80 67 66 -1.49 33 32
S50 50 59 +18.00 12 14
S100 53 59 +11.32 15 17
Note: The adjusted rates are derived by decreasing (for eletriptan) and increasing (for sumatriptan) the SM1 results by amounts that reﬂect the difference in the
conventional 2-hours headache response rates in this speciﬁc study and in the overall eletriptan trial program (for eletriptan) and in the meta-analysis produced by
Tfelt-Hansen [30] (for sumatriptan). It is assumed that there is consistency between the 2-hours headache response rate and the SM1 outcome measure.
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meta-analysis of 53 trials of oral triptans in the
acute treatment of migraine [31]. The SM1 outcome
measure used in the cost-effectiveness analysis has
the same construction as sustained pain-free and is
therefore in line with current thinking in this area.
It should be noted that with both SM1 and sus-
tained pain-free, instances of regression to mild
headache without prompting further medication
use are not counted as recurrences because they are
not deemed to be clinically signiﬁcant [32]. It is not
clear, however, that such mild recurrences are truly
insigniﬁcant from the patient’s perspective. In real-
ity, they might, for example, impose some limitation
on the performance of usual activities. The outcome
measure may be regarded as falling short of the
“ideal” in a number of other respects. In a study by
Lipton and Stewart [33], rapid onset of action was
the third most frequently cited attribute of treat-
ment regarded as very important by patients (fol-
lowing freedom from pain and the absence of
recurrence). The second successful treatment crite-
rion (SM2) employed in this article seeks to take
this into account by incorporating an early indica-
tion of potential treatment effectiveness—that is, an
improvement in headache to pain-free or mild pain
at the 1-hour time point—into the outcome meas-
ure. This is clearly a much stricter test of effective-
ness—for example, under SM2 attacks with a
nonresponse at 1 hour would be deemed treatment
failures even if they became pain-free at 2 and
4 hours with no recurrence or use of rescue medi-
cation—and is inevitably associated with marked
reductions in treatment success rates.
Beyond these considerations, it is axiomatic that
therapeutic success in migraine is not solely a func-
tion of the effectiveness or otherwise of treating
headache. The occurrence of side effects and their
tolerability should also be taken into account. The
extent to which other symptoms associated with
migraine such as nausea, photophobia, and photo-
phonia are alleviated and the speed with which
return to normal functioning is facilitated are addi-
tional factors that arguably should be incorporated
into more comprehensive measures of treatment
outcome in migraine. Alongside the implied require-
ment to continue to reﬁne the content of migraine
speciﬁc outcome measures—not only establishing
the appropriate items but determining their relative
weightings as well—attention also must be given to
questions about the appropriate number of attacks
over which treatment effectiveness should be eval-
uated and the settings in which such assessment
should take place. Finally, while the nature of the
clinical trial on which the present study has been
based meant that only medication costs could be
addressed, a truly comprehensive economic evalua-
tion of the acute treatment options for migraine
would need to take account of the other elements of
resource utilization—especially primary care con-
sultations—required by the management of the
disorder.
Conclusion
A  challenging  research  agenda  faces  the  clinical
and economic evaluation of acute treatments for
migraine. Nevertheless, from an economic perspec-
tive, the present study suggests that cost-
effectiveness offers a helpful analytical framework
for examining the relative value-for-money offered
by the growing number of antimigraine medicines.
More speciﬁcally, its application to an economic
comparison of eletriptan and sumatriptan, reported
here, indicates that the former treatment is associ-
ated with a lower cost per successfully treated
attack. Thus, employing the SM1 measure of out-
come (sustained pain-free), the cost per successfully
treated attack for eletriptan 40 mg is 27% of that
found for sumatriptan 50 mg. Comparing eletriptan
80 mg and sumatriptan 100 mg, the corresponding
value is 39%. These results suggest that eletriptan
has a potentially important contribution to make to
the cost-effective management of migraine.
This study was supported by Pﬁzer Global Research and
Development.
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